The healthcare giant just delivered another strong quarter, and Wall Street's starting to pay attention.

While it may not be a steal of a deal, with the business on the cusp of some exciting growth, Johnson & Johnson's stock could prove to be a good long-term buy. It's already seen as a safe-haven type of stock to own, as it pays a solid dividend that yields 2.3%. Adding more growth to the mix could help it soar higher in the years ahead.

After a strong performance in 2025, Johnson & Johnson is starting the new year right.

In the nearly nine months spanning from May 2025 to February 2026, Johnson & Johnson (JNJ)’s stock experienced a remarkable 52% increase, driven

Johnson & Johnson remains a buy as business momentum accelerates, with Q4 revenue up 9.1% YoY and strong U.S. sales resilience.

Johnson & Johnson is a picture of stability.

Johnson & Johnson (NYSE:JNJ) received FDA approval for DARZALEX FASPRO in combination with D-VRd. The regimen is approved for adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Hindsight is always 20/20, and nowhere is this more evident than in the stock market. But that doesn’t stop investors from trying to determine what they would have made if they had actually invested in a stock they were considering. With this in mind, if ...

Johnson & Johnson (NYSE: JNJ) is a big name in healthcare. People all over the world are familiar with the brand of Johnson & Johnson. And investors have grown to love its dividend, which the company has been increasing for 61 consecutive years. Twenty ...

Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer commented on. Cramer showed an optimistic sentiment toward the stock, as he commented: Lilly’s not alone. The irrepressible Johnson & Johnson,